Crispr Therapeutics Ag - Total Collaboration Revenue for Q3 $0.1 Million Versus $211.9 Million.
Crispr Therapeutics Ag - Q3 Net Loss Was $92.4 Million Versus Net Income of $138.4 Million for Q3 2019.
Crispr Therapeutics - Received Rare Pediatric Disease Designation From FDA for Ctx001 for Sickle Cell Disease & Transfusion-dependent Beta Thalassemia.
Crispr Therapeutics Ag - Received Orphan Drug Designation for Phase 1 Clinical Trial of Ctx120, Targeting B-cell Maturation Antigen.
Crispr Therapeutics Ag - Began Treating Patients in Two Phase 1 Clinical Trials of Ctx130,.
Crispr Therapeutics Ag - to Report Clinical Data From More Patients Treated With Ctx001 in Addition to Data From Patients With Longer Follow-up in Q4.
Adjusted EPS is expected to be -$1.17
Next Quarter Revenue Guidance is expected to be $2.47 Million
Next Quarter EPS Guidance is expected to be -$1.17
More details on our Analysts Page.